Development and Diagnostic Potential of a Novel Bartonella henselae-Specific Immunoglobulin.

Autor: Daughtry A; Institute for Biomarker Research, Genesis Global Group, Hamilton Township, New Jersey, USA., Swanson R; Venenum Biodesign, Genesis Global Group, Hamilton Township, New Jersey, USA., Adelson M; Genesis Global Group, Hamilton Township, New Jersey, USA., Mordechai E; Genesis Global Group, Hamilton Township, New Jersey, USA., Trama J; Institute for Biomarker Research, Genesis Global Group, Hamilton Township, New Jersey, USA. Electronic address: jtrama@ibr-genetics.com.
Jazyk: angličtina
Zdroj: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2024 Sep; Vol. 110 (1), pp. 116381. Date of Electronic Publication: 2024 Jun 13.
DOI: 10.1016/j.diagmicrobio.2024.116381
Abstrakt: Bartonella henselae is a gram-negative rod-shaped bacterium and is the primary causative agent of Cat Scratch Disease (CSD). Although the prevalence of CSD is low in the human population, the possibility of developing multi-organ complications, especially in vulnerable individuals, remains a serious cause for concern. The immunofluorescent assay (IFA) is currently one of the most common laboratory tests for the detection of antibodies to B. henselae in serum, however, it has several disadvantages. The enzyme-linked immunosorbent assay (ELISA) technique offers a more quantitative, sensitive, and cost-effective alternative to conventional IFAs. Here, we report the purification of a novel bioidentical polyclonal antibody from discarded human serum for use as a standard in ELISAs against B. henselae. This novel method of antibody production overcomes the many limitations of animal-derived antibodies while also offering a more robust, reproducible, and scalable antibody production alternative for the diagnosis of CSD.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Annette Daughtry reports financial support and equipment, reagents, or supplies were provided by Genesis Global Group. Jason Trama reports financial support, administrative support, and article publishing charges were provided by Genesis Global Group. Robert Swanson reports financial support and equipment, reagents, or supplies were provided by Genesis Global Group. Martin Adelson reports financial support, administrative support, and article publishing charges were provided by Genesis Global Group. Eli Mordechai reports financial support, administrative support, and article publishing charges were provided by Genesis Global Group. Annette Daughtry reports a relationship with Genesis Global Group that includes: employment. Robert Swanson reports a relationship with Genesis Global Group that includes: employment. Martin Adelson reports a relationship with Genesis Global Group that includes: employment and non-financial support. Eli Mordechai reports a relationship with Genesis Global Group that includes: employment and non-financial support. Jason Trama reports a relationship with Genesis Global Group that includes: employment and non-financial support. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: